Let's check the charts and indicators.
I'm going both ways in what I view as an overbought market within a deteriorating economy.
Let's review the charts of XBI, the SPDR S&P Biotech ETF.
Let's check on the charts and indicators of the cutting-edge CRISPR editing company.
The biotech giant's charts have displayed weakness of late as it prepares to report fourth-quarter results.
A rally in the shares stalled around $180 in December and early January.
These stocks are displaying bearish tendencies based on their technical patterns.
Let's see how to trade GlycoMimetics, a clinical-stage drug developer focused on a type of cancer treatment.
We have two price target areas for this biopharmaceutical firm.
An oncology and a oil & gas concern, new names on my list, have my attention.